De-escalating Immunotherapy in dMMR Colorectal Cancer: Results from the RESET Trials

Clinical oncologist Laurids Poulsen shares new data from the Danish RESET-R and RESET-C trials, exploring reduced immunotherapy in dMMR rectal and colon cancer. Results show a 100% clinical complete response rate in rectal cancer with limited treatment and strong responses in early-stage colon cancer, highlighting potential for less intensive therapy and non-operative management strategies.